Basic information Safety Supplier Related

bimekizumab

Basic information Safety Supplier Related

bimekizumab Basic information

Product Name:
bimekizumab
Synonyms:
  • bimekizumab
  • Research Grade Bimekizumab(DHH28803)
  • Anti-IL-17-mAb-UCB
  • Anti-IL-17-monoclonal-antibody-UCB
  • Anti-interleukin-17-monoclonal-antibody-UCB
  • Research Grade Bimekizumab
  • Bimekizumab (anti-IL17A&IL-17F)
CAS:
1418205-77-2
MW:
0
Mol File:
Mol File
More
Less

bimekizumab Chemical Properties

form 
Liquid
color 
Colorless to light yellow
More
Less

bimekizumab Usage And Synthesis

Uses

Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation[1].

IC 50

IL-17A; IL-17F

References

[1] Shah M, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6(2):e001306. DOI:10.1136/rmdopen-2020-001306

bimekizumabSupplier

Wuhan Sunrise Technology Development Co., Ltd.
Tel
27-027-83314682 13554138826
Email
whsrtech@vip.163.com
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
More
Less